Brain NAD in Alzheimer's disease study
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a natural substance called NAD can improve brain health in people with early Alzheimer's. You may be eligible if you have a firm Alzheimer's diagnosis, are between 65 and 80, and can walk and talk without help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 65 and 80 years old.
- You have a doctor-confirmed Alzheimer's diagnosis with a positive amyloid PET, spinal fluid, or blood test.
- You can walk, talk, and come to the FAU clinic in Florida.
- You do not have advanced dementia, a seizure history, or cancer in the last 5 years (except minor skin cancers).
- You do not take Leqembi or Kinsula infusions, and you can safely have an MRI (no metal implants).
- You do not work night shifts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
This trial tests whether NPC-1, a new drug, can help people with early memory changes or Alzheimer's. Your blood or PET scan will show if you have Alzheimer's-related brain changes, which is required for this study.
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.